Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeNeSIS: Genetics and Neuroendocrinology of Short Stature International Study
2006-001721-26Phase 4Terminated
- Sponsor
- Eli Lilly and Company
- Start
- May 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of somatropin in growth disorder, growth hormone deficiency (GHD) and SHOX deficiency disorder, sponsored by Eli Lilly and Company. Primary endpoint: Collection of clinical, biochemical and genetic data. Started May 2006; status: terminated.
02
Drugs
somatropin
03
Conditions
growth disordergrowth hormone deficiency (GHD)SHOX deficiency disorder
Beyond the preview
Go deeper on 2006-001721-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001721-26.